Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients

被引:54
作者
Bloom, R. D. [1 ]
Lake, J. R.
机构
[1] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Minnesota, Sch Med, Liver Transplantat Program, Rochester, MN USA
关键词
diabetes; hepatitis C virus; kidney transplantation; liver transplantation;
D O I
10.1111/j.1600-6143.2006.01457.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hepatitis C virus (HCV) infection is a major health care issue in liver and kidney transplantation. Besides negatively affecting both patient and graft survival, HCV is associated with a heightened risk for new onset diabetes mellitus (NODM). The mechanisms underlying the diabetogenicity of HCV are complex but are likely to involve insulin resistance caused by inhibitory actions of the virus on insulin regulatory pathways in the liver. The resultant glucose dysregulation is an important determinant of increased morbidity and mortality in liver and kidney recipients. This review highlights the concerns for outcomes in HCV-positive liver and kidney transplant patients with particular focus on the interrelationship between hepatitis C and diabetes. Data about the potential role of calcineurin inhibitors, corticosteroids and mycophenolate mofetil in HCV infection and HCV-associated NODM will also be discussed.
引用
收藏
页码:2232 / 2237
页数:6
相关论文
共 32 条
[21]   Hepatitis C virus infection and human pancreatic β-cell dysfunction [J].
Masini, M ;
Campani, D ;
Boggi, U ;
Menicagli, M ;
Funel, N ;
Pollera, M ;
Lupi, R ;
Del Guerra, S ;
Bugliani, M ;
Torri, S ;
Del Prato, S ;
Mosca, F ;
Filipponi, F ;
Marchetti, P .
DIABETES CARE, 2005, 28 (04) :940-941
[22]   Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy [J].
Neff, GW ;
Montalbano, M ;
O'Brien, CB ;
Nishida, S ;
Safdar, K ;
Bejarano, PA ;
Khaled, AS ;
Ruiz, P ;
Slapak-Green, G ;
Lee, M ;
Nery, J ;
De Medina, M ;
Tzakis, A ;
Schiff, ER .
TRANSPLANTATION, 2004, 78 (09) :1303-1307
[23]   Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up [J].
Neumann, UP ;
Berg, T ;
Bahra, M ;
Puhl, G ;
Guckelberger, O ;
Langrehr, JM ;
Neuhaus, P .
TRANSPLANTATION, 2004, 77 (02) :226-231
[24]   THE IMPACT OF PRETRANSPLANTATION HEPATITIS-C INFECTION ON THE OUTCOME OF RENAL-TRANSPLANTATION [J].
PERIERA, BJG ;
WRIGHT, TL ;
SCHMID, CH ;
LEVEY, AS .
TRANSPLANTATION, 1995, 60 (08) :799-805
[25]  
Roth D, 2004, AM J TRANSPLANT, V4, P289
[26]   Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular β-catenin and stimulation of β-catenin-responsive transcription [J].
Street, A ;
Macdonald, A ;
McCormick, C ;
Harris, M .
JOURNAL OF VIROLOGY, 2005, 79 (08) :5006-5016
[27]   Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy [J].
Triantos, C ;
Samonakis, D ;
Stigliano, R ;
Thalheimer, U ;
Patch, D ;
Burroughs, A .
TRANSPLANTATION, 2005, 79 (03) :261-268
[28]   A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years [J].
Vicenti, F ;
Jensik, SC ;
Filo, RS ;
Miller, J ;
Pirsch, J .
TRANSPLANTATION, 2002, 73 (05) :775-782
[29]   Hepatitis C in renal transplantation [J].
Vosnides, GG .
KIDNEY INTERNATIONAL, 1997, 52 (03) :843-861
[30]   Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes [J].
Watashi, K ;
Hijikata, M ;
Hosaka, M ;
Yamaji, M ;
Shimotohno, K .
HEPATOLOGY, 2003, 38 (05) :1282-1288